Inhibition of the uncoating of bovine enterovirus by short chain fatty acids

References

1. Brown F., Cartwright B. 1963; Purification of radioactive foot- and-mouth disease virus. Nature; London: 1991169–1170
   [Google Scholar]
2. Chow M., Newman J. F. E., Filman D., Hogle J. M., Rowlands D. J., Brown F. 1987; Myristylation of picomavirus capsid protein VP4 and its structural significance. Nature; London: 327482–486
   [Google Scholar]
3. Diana G. D., Salvador U. J., Zulay E. S., Johnson R. E., Collins J. C., Johnson D., Hinshaw W. B., Lorenz R. R., Thielking W. H., Pancic F. 1977; Antiviral activity of some β-diketones. I. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses. Journal of Medicinal Chemistry 20:750–756
   [Google Scholar]
4. Everaert L., Vrijsen R., Boeyé A. 1989; Eclipse products of poliovirus after cold-synchronized infection of HeLa cells. Virology 171:76–82
   [Google Scholar]
5. Ishutsuka H., Ninomiya Y., Ohsawa C., Fujiu M., Suhara Y. 1982; Direct and specific inactivation of rhinovirus by a chalcone, Ro 09–0410. Antimicrobial Agents and Chemotherapy 22:617–621
   [Google Scholar]
6. Kenny M. T., Torney H. L., Dulworth J. K. 1988; Mechanism of action of the antiviral compound MDL 20,610. Antiviral Research 9:249–261
   [Google Scholar]
7. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature; London: 227680–685
   [Google Scholar]
8. Lonberg-Holm K., Noble-Harvey J. 1973; Comparison of in vitro and cell-mediated alteration of a human rhinovirus and its inhibition by sodium dodecyl sulphate. Journal of Virology 12:819–826
   [Google Scholar]
9. Lonberg-Holm K., Gosser L. B., Kauer J. C. 1975; Early alteration of poliovirus in infected cells and its specific inhibition. Journal of General Virology 27:329–342
   [Google Scholar]
10. Mcferran J. B. 1962; Bovine enteroviruses. Annals of the New York Academy of Sciences 101:436–443
    [Google Scholar]
11. Mcsharry J. J., Caliguiri L. A., Eggers H. J. 1979; Inhibition of uncoating of poliovirus by Arildone, a new antiviral drug. Virology 97:307–315
    [Google Scholar]
12. Ninomiya Y., Ohsawa C., Aoyama M., Umeda I., Suhara Y., Ishutsuka H. 1984; Antivirus agent, Ro 09–0410, binds to rhinovirus specifically and stabilizes the virus conformation. Virology 134:269–276
    [Google Scholar]
13. Otto M. J., Fox M. P., Fancher M. J., Kuhrt M. F., Diana G. D., Mckinley M. A. 1985; In vitro activity of WIN 51711, a new broad-spectrum anti-picornavirus drug. Antimicrobial Agents and Chemotherapy 27:883–886
    [Google Scholar]
14. Paul A. V., Schultz A., Pincus S. E., Oroszlan S., Wimmer E. 1987; Capsid protein VP4 of poliovirus is N-myristoylated. Proceedings of the National Academy of Sciences U.S.A: 847827–7831
    [Google Scholar]
15. Rossmann M. G. 1989; The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Antiviral Research 11:3–14
    [Google Scholar]
16. Smith T. J., Kremer M. J., Lou M., Vriend G., Arnold E., Kamer G., Rossmann M. G., Mckinley M. A., Diana G. D., Otto M. J. 1986; The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233:1286–1293
    [Google Scholar]
17. Tisdale M., Selway J. W. T. 1984; Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type IB. Journal of Antimicrobial Chemotherapy 14:97–105
    [Google Scholar]